GlassScriptPhysician profile
Erica L Roach
NPI 1386282655
$3,847.69
in general payments reported to CMS, 2019-2025
25 companies · $737 in 2025
The $737 reported for 2025 was more than what 80% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $987 · 2023: $883 · 2024: $1,001 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,620.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $568.49 | 2022-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $509.50 | 2022-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $332.79 | 2021-2024 | Acthar, Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.71 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $242.41 | 2022-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $240.52 | 2022-2025 | Farxiga |
| Opko Pharmaceuticals, LLC | $224.74 | 2022-2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $213.45 | 2022-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $185.30 | 2023-2025 | |
| Ardelyx, INC. | $166.66 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $155.55 | 2021-2022 | |
| Novo Nordisk INC | $127.51 | 2023-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $125.09 | 2022-2023 | Gattex |
| Shield Therapeutics INC | $86.07 | 2025 | |
| Ani Pharmaceuticals, INC. | $56.72 | 2025 | Purified Cortrophin Gel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $46.88 | 2022-2025 | Benlysta |
| Xeris Pharmaceuticals, INC. | $46.10 | 2023-2024 | Keveyis |
| Fresenius USA Marketing, INC. | $44.95 | 2022-2024 | Nxstage System One, Liberty Select Cycler |
| Kyowa Kirin, INC. | $35.40 | 2024 | Crysvita |
| Otsuka America Pharmaceutical, INC. | $34.31 | 2022 | |
| Daiichi Sankyo INC. | $29.30 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.23 | 2025 | |
| Pharmacosmos Therapeutics INC. | $20.37 | 2022 | |
| Apellis Pharmaceuticals, INC. | $20.05 | 2025 | |
| Travere Therapeutics, INC. | $18.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.